Correlation Between the Kinetics of CD3+ Chimerism and the Incidence of Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Peripheral blood cells chimerism after unrelated cord blood transplantation in children: kinetics, predictive factors and impact on post‐transplant outcome

“…On the contrary, we found a clear correlation between cDC and the risk of GvHD. This relationship has been extensively described after bone marrow or peripheral blood transplant (Mohty et al , ; Svenberg et al , ; Rupa‐Matysek et al , ; Nikolousis et al , ; Stikvoort et al , ). We demonstrated here that this correlation is particularly strong after UCBT.…”

“…Real‐time quantitative polymerase chain reaction (qPCR) currently allows post‐transplant detection of donor and/or host genomic‐specific markers in the host nucleated blood cells with a 0·1% sensitivity (Alizadeh et al , ). In the context of bone marrow or peripheral blood transplantation, many studies have highlighted that the level of donor chimerism influences the occurrence of graft‐versus‐host disease (GvHD) and, in the case of patients with malignant diseases, the risk of disease relapse (Bader et al , ; Lamba et al , ; Saito et al , ; Svenberg et al , ; Rupa‐Matysek et al , ). During the two last decades, the use of unrelated umbilical cord blood (UCB) as an alternative source of HSCT has increased substantially, especially for children (Rocha et al , ; Gluckman et al , ; Eapen et al , ; Barker et al , ).…”

Preferential depletion of host over donor T cells through in vivo decay of active rabbit-anti-thymocyte globulin levels during reduced intensity conditioning

“…7 A recent study found that T-cell chimerism on day 30 correlated with the occurrence of extensive chronic but not acute GvHD. 17 Extensive chronic GvHD was seen in 60% of patients in our study but was fatal in only four patients (17%) on prolonged follow-up. Although chronic GvHD may be protective against late disease relapse, it may also impair quality of life for those affected.…”

The practical application of chimerism analyses in allogeneic stem cell transplant recipients: Blood chimerism is equivalent to marrow chimerism

“…There is also a wide range of practices for the clinical use of chimerism analyses with some institutions using chimerism as a measure of engraftment, a measure of minimal residual disease, and some institutions that do not use chimerism analyses. Additionally, chimerism studies are frequently done on cell subsets like CD 34 positive cells, T-cells, T-cell subsets, and NK-cells (Breuer et al, 2012;Lange et al, 2011;Miura et al, 2006;Rupa-Matysek et al, 2011;Tobiasson et al, 2011). There are no consensus guidelines for using subset analyses in clinical practice.…”